SLC5A2 and diabetes mellitus: Sodium–glucose cotransporter-2 (SGLT2) inhibitors are an essential element of cardiovascular and renal prevention in complicated diabetes, and their introduction into clinical practice opened up new opportunities for prevention and therapy of diabetic complications [2,5,6,7].